

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

HESTERKAMP *et al.*

Appl. No.: To be assigned (*U.S. Nat'l Phase of PCT/EP2004/013111*)

I.A. Filing Date: November 18, 2004

For: **Diagnostic and Therapeutic Use of the Human SGPL1 Gene and Protein for Neurodegenerative Diseases**

Confirmation No.: *To be assigned*

Art Unit: *To be assigned*

Examiner: *To be assigned*

Atty. Docket: 2335.0150000/SRL/KPQ

**Authorization to Treat a Reply as Incorporating an
Extension of Time Under 37 C.F.R. § 1.136(a)(3)**


Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

The U.S. Patent and Trademark Office is hereby authorized to treat any concurrent or future reply that requires a petition for an extension of time under this paragraph for its timely submission, as incorporating a petition for extension of time for the appropriate length of time. The U.S. Patent and Trademark Office is hereby authorized to charge all required extension of time fees to our Deposit Account No. 19-0036, if such fees are not otherwise provided for in such reply.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Katrina Y. Pei Quach
Agent for Applicants
Registration No. 51,063

Date: May 18, 2006

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600